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Abstract
Background: Impaired microcirculation during endotoxemia correlates with a disturbed arginine-nitric oxide (NO)
metabolism and is associated with deteriorating organ function. Improving the organ perfusion in endotoxemia, as often
seen in patients with severe infection or systemic inflammatory response syndrome (SIRS) is, therefore, an important
therapeutic target. We hypothesized that supplementation of the arginine precursor citrulline rather than arginine would
specifically increase eNOS-induced intracellular NO production and thereby improve the microcirculation during
endotoxemia.
Methodology/Principal Findings: To study the effects of L-Citrulline and L-Arginine supplementation on jejunal
microcirculation, intracellular arginine availability and NO production in a non-lethal prolonged endotoxemia model in mice.
C57/Bl6 mice received an 18 hrs intravenous infusion of endotoxin (LPS, 0.4 mgNg bodyweight
21Nh
21), combined with either
L-Citrulline (6.25 mgNh-1), L-Arginine (6.25 mgNh
21), or L-Alanine (isonitrogenous control; 12.5 mgNh
21) during the last 6 hrs.
The control group received an 18 hrs sterile saline infusion combined with L-Alanine or L-Citrulline during the last 6 hrs. The
microcirculation was evaluated at the end of the infusion period using sidestream dark-field imaging of jejunal villi. Plasma
and jejunal tissue amino-acid concentrations were measured by HPLC, NO tissue concentrations by electron-spin resonance
spectroscopy and NOS protein concentrations using Western blot.
Conclusion/Significance: L-Citrulline supplementation during endotoxemia positively influenced the intestinal microvas-
cular perfusion compared to L-Arginine-supplemented and control endotoxemic mice. L-Citrulline supplementation
increased plasma and tissue concentrations of arginine and citrulline, and restored intracellular NO production in the
intestine. L-Arginine supplementation did not increase the intracellular arginine availability. Jejunal tissues in the L-
Citrulline-supplemented group showed, compared to the endotoxemic and L-Arginine-supplemented endotoxemic group,
an increase in degree of phosphorylation of eNOS (Ser 1177) and a decrease in iNOS protein level. In conclusion, L-Citrulline
supplementation during endotoxemia and not L-Arginine reduced intestinal microcirculatory dysfunction and increased
intracellular NO production, likely via increased intracellular citrulline and arginine availability.
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Introduction
XEndotoxemia and inflammatory conditions, such as sepsis are
associated with multiple-organ failure. This organ failure is caused
by a dysfunctional organ perfusion at the microcirculatory level
[1–3], which makes organ perfusion an important therapeutic
target [4,5]. Endotoxemia and inflammation-induced perturba-
tions in organ perfusion are characterized by redistribution of
blood flow between and within organs at the microcirculatory level
and lead to ischemia in critical tissues such as lung, liver and gut
[6–8]. Especially the villi of the small intestine are sensitive to a
decreased blood flow and suffer from microcirculatory distur-
bances during endotoxemic conditions such as severe inflamma-
tion and sepsis [9–11]. Previous experimental and clinical studies
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37439demonstrated that hepatosplanchnic hypoperfusion is related to
intestinal mucosal damage, impaired tissue oxygenation and an
increase in inflammatory mediators [6,12–14].
An imbalance in Nitric Oxide (NO) metabolism at the
cellular level, especially the endothelium, is thought to play a
crucial role in the development of endotoxemic-related micro-
circulatory disturbances, such as in sepsis [15–18]. NO is
produced by the conversion of arginine into citrulline by one of
the three isoforms of nitric-oxide synthase (NOS) and is thought
to depend largely on extracellular arginine availability, which is
decreased during endotoxemia and sepsis [15,17,19]. Several
mechanisms were proposed to explain arginine deficiency in
diseases with an increased arginine catabolism such as
endotoxemia and sepsis. Especially, enhanced activity of
Arginase-1 [20,21] and iNOS (NOS2), but also diminished de
novo arginine synthesis from citrulline and a diminished de novo
citrulline synthesis are relevant mechanism which contribute to
arginine deficiency [17,19,22]. iNOS can produce excessive
amounts of NO during endotoxemia, which contributes to the
decreased arterial pressure and abnormal distribution of the
blood flow in the microcirculation [18,23,24]. The resulting low
plasma arginine levels may lead to decreased intracellular
substrate availability in the microvasculature for eNOS (NOS3)
[17]. This decreased substrate availability in combination with
endotoxemia-induced eNOS downregulation results in decreased
eNOS-mediated NO production, which is considered to result
in the microcirculatory disturbances in sepsis [25]. Interestingly,
L-Arginine supplementation in prolonged endotoxemia and
sepsis failed to increase the intracellular NO production despite
increased arginine plasma availability [26–30], hypothetically
because the intracellular arginine does not increase during L-
Arginine supplementation [15,22].
The co-localization of eNOS and ASS in the caveola of the
endothelial cells indicates a tight intracellular coupling between
citrulline, arginine and the NO metabolism [27]. The presence of
ASS in endothelial cells offers the opportunity to use L-Citrulline
supplementation to increase intracellular endothelial arginine
availability for NO production [16,22,27] and, thereby, to
ameliorate microcirculatory dysfunction. We therefore hypothe-
size that L-Citrulline supplementation could improve splanchnic
microcirculation by increasing the intracellular citrulline, arginine
and NO availability. Therefore, we investigated the effects of L-
Citrulline and L-Arginine supplementation on the microcircula-
tion, the intracellular arginine availability and NO production in
a murine prolonged endotoxemia model.
Materials and Methods
Additional details about animals and procedures are provided in
the Methods S1.
Animals
Sixty-five male C57/Bl6 mice with a mean weight of 27 g
(range 26–28.5) were obtained from the Central Animal Facilities
of the Maastricht University Medical Center. The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Maastricht University Medical Center (Permit Number:
2008-042 and 2010-172). (additional details in the online
Methods S1).
Experimental Protocol
Four days prior to the experimental period, mice received a
jugular vein catheter (Silclear tubing, MEDNET, Mu ¨nster,
Germany) which was fixed to the head with glass ionomer cement
(FuijCEM Automix, Instech Solomon, Plymouth Meeting, PA).
Mice (n=65) were randomly allocated to an 18 hour infusion with
eithersterile0.9%saline(n=26)orlipopolysaccharide(LPS;E.Coli
O55:B5, Sigma Aldrich, St. Louis, MO) (n=39) (Figure 1). LPS
(0.4 mgNg bodyweight
21Nh
21) was administered with a continuous
flow rate of 83 mL/h. In the final 6 hours of the LPS infusion, L-
Citrulline (1.25 g/kg total; n=13; ‘‘LPS-Cit’’ group), L-Arginine
(1.25 g/kg total; n=13; ‘‘LPS-Arg’’ group) or an isonitrogenous
dosage of the placebo amino acid L-Alanine (2.5 g/kg total; n=13;
‘‘LPS-Ala’’ group) was added to the LPS infusate. All mice survived
the experiments. To determine the clinical manifestations of
endotoxemia a semi-quantitative evaluation score was developed.
Contents of the score were based on the specific endpoints used in
previous endotoxemia models in small laboratory animals of our
group [31,32] and from the human endpoints for infectious animal
models [33]. These characteristic clinical manifestations of endo-
toxemia (piloerection/erection of the fur, exudates around the eyes
and nostrils, lethargy, hypothermia, diarrhea and diminished
locomotor activity) were scored by the animal care taker, blinded
for treatment. A 2-points (absent/present) score was used for
lethargy, hypothermia and diarrhea, and a 3-points score (absent/
moderate/severe) for the evaluation of piloerection/erection of the
fur, exudates around the eyes/nostrils and diminished locomotor
activity.
The L-Citrulline and L-Arginine dosages were extrapolated
from the arginine dosages used in both porcine endotoxemia [34]
and a human arginine supplementation study (Luiking, Poeze,
Deutz, unpublished data), taking in consideration that the nitrogen
Figure 1. Experimental set up of the prolonged endotoxemia model. Mice were fitted with a jugular vein cannula at t=0 d. After 4 days
(t=4 d) an 18hours continuous infusion with lipopolysaccharides (LPS) was started, which was combined during the last 6 hours with an infusion of
Citrulline (Cit), Arginine (Arg) or an isonitrogenous quantity of the placebo Alanine (Ala). After completing the treatment, sidestream dark-field (SDF)
imaging was used to quantify the microcirculation in the jejunal villi or Nitric Oxide (NO) spin trapping with iron-diethyldithiocarbamate (DETC)
complexes to measure NO production in vivo.
doi:10.1371/journal.pone.0037439.g001
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[35,36].
The control group was treated with 0.9% saline and L-Alanine
(n=13; ‘‘control’’ group). To investigate the role of L-Citrulline
supplementation during physiological conditions mice were
treated with 0.9% saline and L-Citrulline (n=13, ‘‘NaCl-Cit’’-
group, data displayed in the online supplemental material). In
total, mice received 1.5 mL fluid intravenously during the
experimental period. Throughout final experiments (microcircu-
lation, NO measurements, blood/tissue sampling), body temper-
ature was maintained at 37uC using a heating pad and an infrared
heating lamp with temperature controller connected to a rectal
probe (Technical Service, Maastricht University). The mean
arterial pressure (MAP) was measured during the microcirculatory
measurements. In brief, a polyethylene tubing was inserted in the
right carotid artery and connected to a low-volume pressure
transducer to register the MAP (additional details in the
online Methods S1).
Microcirculation Measurements
After the 18 hours infusion, mice (n=40) were anaesthetized
and a small segment of the jejunum was exteriorized after a
midline incision in the abdomen. A longitudinal incision in the
jejunal segment was made to microscopically visualize the
microcirculation in the mucosa with a sidestream dark-field
(SDF) imager [37,38]. The surgical procedure is based on the
technique used by Massberg et al. [39] who used intravital
fluorescence microscopy to evaluate the mucosal jejunal micro-
circulation. A specially designed stand was used to stabilize the
SDF imager and to prevent pressure on the tissue or camera
movement during the measurements. In addition, the microcir-
culation, defined as number of perfused microcirculatory vessels
(diameter #10 mm) and the total number of perfused vessels
(1 mm#diameter#50 mm) were measured and analyzed with
Image J and Matlab. Furthermore, the characteristics of the
microcirculation according to de Backer et al [2,40,41] were
analyzed using the Automated Vascular Analysis software 3.0
(Microscan, Amsterdam, The Netherlands). Since Ava 3.0 was
developed to analyze the sublingual microcirculation, adjustments
as suggested by de Backer et al were made to analyze the jejunal
microcirculation [40]. In brief, the average microvascular flow
index (MFI), the determination of the predominant type of flow in
the villi in the four quadrants of the image was determined
(described as 0=absent, 1=intermittent, with at least 50% of the
time no flow, 2=sludging, 3=normal or 4=hyperdynamic flow)
[2]. The percentage of perfused villi (%) was calculated based on
the number of perfused villi per field divided by the total number
of villi per field. The total vessel density (TVD; mm/mm
2) was
Figure 2. Circulation measurements with SDF imaging in the control, LPS-Ala, LPS-Arg and LPS-Cit groups. (A) L-Citrulline
supplementation improved the number (mean6SEM) of measurable perfused vessels in the jejunal microcirculation during endotoxemia, (B) in
particular of vessels with a diameter #10 mm( P ,0.01), compared to LPS-Ala and LPS-Arg supplemented animals. (C) The total number of perfused
vessels per villus and (D) microcirculatory vessels with a diameter #10 mm per villus were also significantly lower in the LPS-Ala and LPS-Arg
supplemented animals compared to the control and LPS-Cit group.
doi:10.1371/journal.pone.0037439.g002
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Ava 3.0 divided by the total length of the lines. The perfused vessel
density (PVD; mm/mm
2) and proportion of perfused vessels (PPV;
%) were calculated based on the TVD and perfusion of these
vessels [40,41] (additional details in the online Meth-
ods S1).
Blood Sampling, Sample Processing and Measurements
of Amino Acids
After the microcirculatory measurements, mice were sacrificed
through a cardiac puncture to collect 600–800 mL arterial blood
for amino acid determination. After sampling, blood was collected
in pre-chilled, heparinized microvettesH (Sarstedt, Nmbrecht,
Germany) on ice and centrifuged immediately (4uC for 15 minutes
at 8,500 g) to obtain plasma. For determination of plasma amino-
acid concentrations, 100 mL plasma was added to 200 mL
acetonitrile, for deproteinization, vortexed and stored at -80uC
until further analysis. To determine tissue amino-acid concentra-
tions, frozen homogenized tissue samples were added to 250 mLo f
5% sulfosalicylic acid and 0.1 g glass beads (1.0 mm diameter) for
deproteinization, beaten for 30 seconds at maximum speed with
the mini-beadbeater (Biospec products) and stored at 280uC until
further analysis. Plasma and tissue arginine, citrulline and
ornithine concentrations were measured with a high-performance
liquid chromatography (HPLC) after automated pre-column
derivatization with o-phthaldialdehyde as previously de-
scribed [42].
In vivo Tissue NO Measurements
In brief, the in vivo NO levels in jejunal tissues (n=30) were
quantified by NO-trapping with Fe
2+-dithiocarbamate complexes
as mono-nitrosyl iron complexes (MNIC) [43]. NO concentrations
were calculated from the height of the three-line NO amplitude
with Bruker WINEPR software as described [43] (additional
details in the online Methods S1).
Protein Isolation and Western Blot Analysis
Protein in the tissue samples was isolated with the AllPrep
DNA/RNA/Protein kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. Western blot membranes were
incubated overnight with rabbit polyclonal anti-mouse iNOS
(Abcam, Cambridge, MA) or rabbit polyclonal anti-mouse
phosphorylated eNOS (Ser1177) (Cell signaling technology,
Danvers, MA) at 46C and incubated with the proper secondary
antibody at room temperature for 1 hour, before capturing the
signals on X-ray film using a chemiluminescent reaction (addi-
tional details in the online Methods S1).
Statistical Analysis
Statistical analysis of the data was performed using SPSS 15.0
(SPSS, Chicago, IL). In case of Gaussian distribution one-way
ANOVA with post-hoc Bonferroni correction between groups was
conducted. A non-parametric Kruskal-Wallis test was performed to
determinesignificanceincaseofanon-Gaussiandistribution.Atwo-
sided P–value,0.05 was considered as statistical significant. Data
are represented as mean and standard error of the mean (SEM).
Figure 3. Representative live images of the microcirculatory measurements in jejunal villi with SDF imaging. (A) Representative live
image of the jejunal microcirculation in a control mouse. (B) Representative live image of the jejunal microcirculation in a LPS-Ala treated mouse
which shows only perfusion of the larger vessels. (C) Representative live image of a LPS-Arg treated mouse which shows a comparable perfusion
pattern as the LPS-Ala treated mouse. (D) Representative live image of a LPS-Cit treated mouse, which’s shows more small perfused vessels per villus.
doi:10.1371/journal.pone.0037439.g003
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Model Characteristics
The characteristic clinical manifestations of endotoxemia
(piloerection/erection of the fur, exudates around the eyes and
nostrils, hypothermia, lethargy, diarrhea and diminished locomo-
tor activity) were present in all three LPS-treated groups.
However, these signs were more pronounced in the LPS-Ala
and LPS Arg group than the LPS-Cit group (See Figure S1). The
average core temperature of the mice prior to the start of the
microcirculatory measurements was significantly lower in the LPS-
Ala (33.861.7uC) and the LPS-Arg groups (33.861.0uC) than in
the control group (35.860.7uC; both P,0.05) and the LPS-Cit
group (35.961.0uC; both P,0.05). Prior to the microcirculatory
measurements an infrared heating lamp with temperature
controller was used to increase the core temperature of the mice,
which resulted in stabilization of the core temperature during the
microcirculatory measurements. The average core temperature of
the mice during the microcirculation measurements did not differ
between groups (36.960.1uC in the control, 35.062.1uC in the
LPS-Ala group, 35.760.5uC in the LPS-Arg and 36.260.9uCi n
the LPS-Cit group).
The mean arterial blood pressure (MAP) during these microcir-
culatorymeasurementswassignificantlyhigherinthecontrolgroup
versus the LPS-Ala group (control versus LPS-Ala, 70.161.8 versus
55.061.5 mmHg; P,0.01). In the L-Citrulline and L-Arginine
supplemented groups the MAP was also significantly higher
compared to the LPS-Ala group (LPS-Cit versus LPS-Ala,
64.761.5 versus 55.061.5 mmHg; P=0.01 and LPS-Arg versus
LPS-Ala, 65.062.8 versus 55.061.5 mmHg; P,0.05). The MAP
wascomparablebetweentheLPS-CitgroupandtheLPS-Arggroup
(LPS-Cit versus LPS-Arg; P=0.9). MAP did not differ significantly
between the control group (70.161.8 mmHg) and the LPS-Cit or
LPS-Arg group (P=0.08 and P=0.2, respectively).
Citrulline Supplementation Improved the
Microcirculation in the Gut During Endotoxemia
Endotoxemia resulted in a significantly decreased total number
of perfused vessels (1 mm#diameter#50 mm) in the LPS-Ala
group compared to control (n=8; P,0.01; Figure 2A). L-
Arginine administration during endotoxemia did not result in a
restoration of the number of perfused vessels (n=8; P,0.05). In
contrast, L-Citrulline supplementation during endotoxemia re-
stored the total number of perfused vessels to nearly the number of
vessels seen in the control group (n=8; P=1.0). The observed
difference in the total number of perfused vessels is caused by the
decreased circulation in the smallest (#10 mm) vessels in the LPS-
Ala and LPS-Arg groups (42.566.5 and 33.764.1, respectively;
Figure 2B). The number of perfused microcirculatory vessels in
the LPS-Cit group was comparable to that in control mice
(Figure 2B). Furthermore, also the total number as well as the
number of small (#10 mm) vessels perfused per villus were
significantly decreased in the LPS-Ala and LPS-Arg group
compared to the control and LPS-Cit treated group (Figure 2C
and 2D). See Figure 3A, 3B, 3C, 3D and the Videos S1, S2,
S3, S4, S5 for representative live images and videos of the
microcirculation in the respective groups. The characteristics of
the microcirculation according to de Backer et al are displayed in
the Supporting Information Table S1. Beneficial effects of L-
Citrulline supplementation for these characteristics were found
compared to the LPS-Ala and LPS-Arg group. L-Citrulline
supplementation during physiological conditions did not influence
the microcirculation (see Supporting Information Table S1
and Figure S2).
Citrulline Enhances Citrulline and Arginine Availability
During Endotoxemia and Resulted in Increased Tissue
NO Concentration
Plasma amino acids. As expected L-Citrulline supplemen-
tation increased plasma citrulline concentration ,20-fold
(P,0.0001) compared to the control, the LPS-Ala and the LPS-
Arg group (Figure 4A). L-Citrulline supplementation during
Figure 4. Amino-acid concentrations in plasma. (A) Citrulline
plasma concentrations increased after L-Citrulline supplementation
(LPS-Cit) compared to all other groups (P,0.0001). (B) Plasma arginine
concentrations were significantly reduced in the LPS-Ala group
compared to the control group (P,0.05), whereas this concentration
was significantly increased by L-Arginine or L-Citrulline supplementa-
tion (LPS-Arg and LPS-Cit group) compared to both other groups
(P,0.001). (C) Plasma ornithine levels increased in the LPS-Ala treated
group compared to the control group (P,0.05) and increased further
upon L-Arginine or L-Citrulline supplementation.
doi:10.1371/journal.pone.0037439.g004
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enhanced plasma citrulline and arginine concentrations versus
control (see Figure S3). Endotoxemia resulted in a significantly
decreased arginine plasma concentration in the LPS-Ala group
compared to control (n=13; P,0.05), comparable to the
metabolic disturbances in man. For a complete description of
the L-arginine concentration during prolonged endotoxemia
infusion see also Figure S4. In the LPS-Cit group the plasma
arginine concentration was significantly increased versus control
mice (n=13; P,0.0001) and the LPS-Ala group (n=13;
P,0.0001). Although, L-Arginine supplementation enhanced the
arginine plasma concentrations in the LPS-Arg group compared to
the concentrations in control mice (n=13; P,0.001; Figure 4B)
and compared to LPS-Ala treated mice (n=13; P,0.0001), these
enhanced arginine levels were significantly lower than those in the
L-Citrulline supplemented group (n=13; P,0.05). The plasma
ornithine concentration was higher in all LPS-treated groups than
in the control group (Figure 4C).
Tissue amino-acid concentrations. The tissue amino-acid
concentrations in all groups exhibited results that were largely
similar to the changes in plasma concentrations. Endotoxemia
resulted in a decreased jejunal tissue arginine concentration in the
LPS-Ala group versus control (n=13; P,0.05), which was
accompanied by a significantly decreased tissue citrulline concen-
tration (n=13; P,0.05, Figure 5A and 5B). Interestingly, the
beneficial effects of L-Arginine supplementation in the LPS-Arg
group on the plasma concentrations was not observed in the
jejunal tissue as the tissue arginine concentration was significantly
decreased compared to control (n=13; P,0.05, Figure 5A).
However, L-Citrulline supplementation during endotoxemia also
enhanced the tissue arginine concentration compared to LPS-Ala
and LPS-Arg treated mice (n=13; both P,0.01). L-Citrulline
supplementation under basal conditions also enhanced the tissue
arginine concentrations (see Figure S3). During endotoxemia
ornithine tissue concentrations increased in the LPS-Ala and LPS-
Cit treated groups compared to the control group, which was in
line with the increase in the plasma concentrations (Figure 5C).
In the LPS-Arg group ornithine tissue concentrations were lower
than in the LPS-Ala group.
Tissue NO production. The jejunal NO production,
detected as MNIC per mg jejunal tissue, decreased in the LPS-
Ala group compared to the control group (n=13, P,0.05). L-
Arginine supplementation during endotoxemia enhanced the NO
production compared to control and LPS-Ala treated animals
Figure 5. Amino-acid concentrations and NO production in murine jejunal tissue. (A) L-Citrulline supplementation (LPS-Cit) increased
tissue citrulline concentration compared to the LPS-Ala, LPS-Arg and control groups (P,0.001) (B) Arginine concentrations were significantly reduced
in the LPS-Ala group compared to the control group (P,0.05). Interestingly, this concentration was not increased by L-Arginine supplementation
(LPS-Arg), whereas this concentration was significantly increased by L-Citrulline supplementation (LPS-Cit group; P,0.01). (C) Ornithine levels
increased in the LPS-Ala treated group compared to the control group (P,0.05) and increased further upon L-Citrulline supplementation (P,0.0001
relative to the control group and P,0.05 relative to the LPS group). (D) In the jejunum, prolonged endotoxemia resulted in a significant decrease in
NO production (measured as pmol mono-nitrosyl-iron complexes (MNIC)/mg wet tissue) compared to control (P,0.05). NO production was
significantly improved in the LPS-Arg and LPS-Cit group compared to the LPS group (P,0.0001 and P,0.05 respectively).
doi:10.1371/journal.pone.0037439.g005
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and P,0.05, respectively; Figure 5D). Also L-Citrulline supple-
mentation resulted in an increased NO production in the jejunum
during basal and endotoxemic conditions compared to the LPS-
Ala treated mice (n=13; P,0.05; Figure 5D; basal data of the
NaCl-Cit group see Figure S5).
Citrulline Supplementation Affects the Expression
Patterns of eNOS and iNOS in Endotoxemia
The extent of eNOS phosphorylation (Ser1177), as marker of
active eNOS, in the jejunal tissue of the LPS-Ala and LPS-Arg
treated groups was significantly decreased compared to the control
group (both P,0.05). Interestingly, L-Citrulline supplementation
to endotoxemic mice resulted in a higher jejunal degree of
Figure 6. Phosphorylated eNOS and iNOS protein levels in murine jejunal tissue. (A) The degree of phosphorylation of eNOS protein
(expressed in arbitrary units, AU) was higher in the LPS-Cit group than in the LPS-Ala and LPS-Arg group (P,0.05). (B) The iNOS protein concentration
changed in an opposite detection, with significantly lower levels in the control (P,0.05) and LPS-Cit group (P,0.01) than in the LPS-Ala and LPS-Arg
group. (C) Representative examples of expression of phosphorylated eNOS (Ser 1177), iNOS and beta-actin by Western blot analysis.
doi:10.1371/journal.pone.0037439.g006
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control mice (n=6 in all groups, all P,0.05; Figure 6A).
Moreover, a lower iNOS protein content was measured in the
LPS-Cit group than in the LPS-Ala and LPS-Arg groups (n=6)
(Figure 6B and 6C:P ,0.001). As expected the LPS-Ala group
showed significantly increased iNOS protein levels compared to
controls (n=6) (Figure 6B: P,0.05).
Discussion
Our study demonstrates beneficial effects of L-Citrulline
supplementation in a mouse model of prolonged endotoxemia.
We provide evidence for microcirculatory improvement with an
increased number of perfused vessels in the microcirculation of
the jejunal villi after L-Citrulline supplementation during
endotoxemia, which was not observed following L-Arginine
supplementation. These positive effects of citrulline appear to be
mediated by increased plasma and tissue arginine availability, an
enhanced presence of active phosphorylated eNOS and lower
iNOS protein levels.
In this study we used a newly developed prolonged murine
endotoxemia model (18 hours) to investigate the disturbances of
the arginine-NO metabolism as reported in patients in whom
prolonged exposure to endotoxin is expected. We, therefore,
consider that this prolonged endotoxemia model mimics the
human metabolic situation during endotoxemia-induced inflam-
matory conditions, in which we demonstrated a deficiency in
arginine availability and associated decreased NO production
during prolonged endotoxemia [44]. Thus far, disturbances in the
arginine-NO metabolism were mainly studied in acute murine
endotoxemia models [22,45–48]. In these models, arginine as
substrate for NO was identified as key factor in development of the
microcirculatory and perfusion disturbances related to endotox-
emia. However, no deficit in the plasma arginine pool, comparable
to the metabolic derangements reported in man, was found
in these acute models [22,45–48]. It should however be mentioned
that one experimental animal study reported significant changes in
the arginine flux in the early stages of endotoxemia [48]. Our new
model was based on a pilot observation in mice that plasma
arginine concentrations decreased below baseline from 12 hours
after the onset of the continuous endotoxin infusion, which is
supported by the observations of Braulio et al [31]. This led us to
use an 18 hours infusion period with endotoxin.
Arginine deficiency in inflammatory conditions has led to
several experimental and human studies investigating modalities
to restore the arginine-induced NO production [28–30,49].
However, a study in critically ill patients supplemented with L-
Arginine did not result in increased whole-body NO production,
as assessed with the conversion of labeled arginine into citrulline
using stable isotopic infusion, despite increased arginine plasma
concentrations (Luiking, Poeze, Deutz, unpublished data). In
addition, also in a model of prolonged porcine endotoxemia,
whole-body NO production was not increased during L-Arginine
supplementation [34]. Here we show that L-Arginine supple-
mentation increased tissue NO production as assessed with ESR
spectroscopy combined with in vivo NO-trapping, while the
jejunal microcirculation did not improve. We consider that a
disbalance between iNOS and eNOS-mediated NO release could
explain the lack of improvement in microcirculation. Under
normal physiological conditions, eNOS activity is central to the
microcirculatory homeostasis. However, during endotoxemia and
inflammation, iNOS is upregulated whereas eNOS expression is
downregulated [25] resulting in a disrupted microvascular
perfusion, a redistribution of the microcirculatory flow, hypoxia,
and eventually organ failure [2,25]. In line, the present study
demonstrated a disturbed microcirculation and low degree in
tissue phosphorylation of eNOS-protein levels in the LPS-Ala
group, which were both not restored by supplementation of L-
Arginine. Moreover, L-Arginine supplementation did not affect
iNOS protein levels compared to the LPS-Ala group. Interest-
ingly, L-Citrulline supplementation resulted in a similar tissue
NO increase, while both arginine and citrulline tissue levels were
increased. We consider that the reduced iNOS protein levels
combined with the enhanced levels of active eNOS and the
enhanced arginine concentrations in tissue following L-Citrulline
supplementation are responsible for the improved microcircula-
tion. These data strongly suggest that the citrulline availability
appears to be the key factor rather than arginine to enhance the
eNOS-derived NO production, to reduce iNOS protein levels
and thereby improve organ perfusion during endotoxemia. This
is supported by an in vitro study by Goodwin et al indicating
intracellular arginine regeneration from citrulline, via the Ass
pathway, to be essential for eNOS-mediated NO production in
endothelial cells [50]. In line with these data, Shen et al. [27]
reported that citrulline is the major arginine pool for eNOS-
mediated NO production, while extracellular arginine forms the
only arginine pool for iNOS-induced NO production [27]. In
line, an enhanced NO production was reported to require not
only increased circulating arginine concentrations, but also
enhanced citrulline availability during endotoxemia [15]. The
effects of L-Citrulline supplementation: enhanced plasma argi-
nine concentration and increased tissue arginine concentration
may indicate that insufficient citrulline availability underlies the
low arginine levels seen in endotoxemic mice [15,17,22]. Such a
therapeutic role of L-Citrulline supplementation is also supported
by very recent data of Elwafi et al [36], who showed that oral
supplementation of L-Citrulline in rats resulted in higher plasma
arginine concentrations compared to L-Arginine supplementation
during acute endotoxemia [36]. In addition, the therapeutic role
of L-Citrulline is not limited to endotoxemic conditions, as L-
Citrulline supplementation has been demonstrated to be bene-
ficial in several other pathological conditions associated with
limited L-Arginine availability or enhanced arginine catabolism
[51–54]. In these (patho)physiological conditions, such as sickle
cell disease, heart failure, and pulmonary hypertension, L-
Citrulline was shown to be more efficient than L-Arginine to
enhance the plasma levels of arginine and the eNOS-derived NO
production. [52–58]. Therefore, L-Citrulline is a promising tool
in raising arginine plasma concentrations and associated endo-
thelial NO-production in diseases with arginine deficiency and
vascular dysfunction.
In conclusion, this study demonstrates that L-Citrulline and not
L-Arginine supplementation during murine endotoxemia im-
proves the microcirculation and results in increased plasma and
tissue availability of citrulline, arginine and NO during endotox-
emia. The positive effects of L-Citrulline supplementation are
paralleled by increased functional eNOS protein levels and
reduced iNOS protein levels during endotoxemia.
Supporting Information
Figure S1 Evaluation of the endotoxemia signs in the
LPS treated groups compared to the control group. The
average clinical signs of endotoxemia were more pronounced in
the LPS-Ala and LPS-Arg group compared to control and LPS-
Cit treated animals. The characteristic clinical manifestations of
endotoxemia (Lethargy, hypothermia, diarrhea, piloerection/
erection of the fur, exudates around the eyes and nostrils and
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37439diminished locomotor activity were scored by the animal care
taker, blinded for treatment on a semi-quantitative 2 (absent/
present) or 3-points (absent/moderate/severe) score. A 2-point
score was used for lethargy, hypothermia and diarrhea and a 3-
point score for piloerection, diminished locomotor activity and
exudates around the eyes and nostrils.Data presented indicate
median, interquartile, and 5%/95% range.
(TIF)
Figure S2 Circulation measurements with SDF imaging
in the NaCl-Cit group compared to control. (A) L-Citrulline
supplementation during physiological conditions did not enhance
the total number (mean6SEM) of measurable perfused vessels in
the jejunal microcirculation, (B) or the vessels with a diameter
#10 mm, compared to control. (C) Also at the villus level, L-
Citrulline supplementation did not enhance the total number of
measurable perfused vessels. (D) A distribution of the number of
perfused vessels per vessel diameter (mm) shows a comparable
number of vessels per group. (E) Also the vessels with a diameter
#10 mm per villus, did not differ between groups.
(TIF)
Figure S3 Plasma and jejunal tissue amino-acid con-
centrations under physiological conditions with or
without L-Citrulline supplementation. (A) Citrulline, argi-
nine and ornithine plasma concentrations increased after L-
Citrulline supplementation NaCl-Cit) compared to control
(P,0.001). (B) Tissue amino-acid concentrations of citrulline,
arginine and ornithine were also significantly increased by L-
Citrulline supplementation under physiological conditions.
(TIF)
Figure S4 Time-course of plasma arginine concentra-
tions during prolonged LPS infusion. Arginine plasma
concentrations initially increased during the first hours of
prolonged endotoxemia. However, arginine plasma concentrations
decreased significantly below basal concentrations after 12 hours
of continuous LPS infusion, which indicated an arginine deficient
state in plasma. Each time point contains plasma concentrations of
6 mice. Data represented in mean 6 SEM.
(TIF)
Figure S5 Intracellular NO production in murine jeju-
nal tissue under physiological conditions with or without
L-Citrulline supplementation. Citrulline supplementation
(NaCl-Cit) did not result in enhanced NO production (measured
as pmol mono-nitrosyl-iron complexes (MNIC)/mg wet tissue
weight) compared to control in murine jejunal tissue.
(TIF)
Table S1 Summary of microcirculatory parameters in
control groups and the LPS-treated groups with/without
citrulline or arginine supplementation. Total vessel density
(TVD; mm/mm
2) was calculated as the number of vessels crossing
the arbitrary lines in Ava 3.0 divided by the total length of the
lines. The perfused vessel density (PVD; mm/mm
2) and
proportion of perfused vessel (PPV; %) were calculated based on
the TVD and perfusion of the total vessels. The microvascular flow
index (MFI) is based on the determination of the predominant type
of flow in the repeating microvascular structure (villi) in the four
quadrants of the image (0=absent, 1=intermittent, with at least
50% of the time no flow, 2=sludging, 3=normal or 4=hyper-
dynamic flow). The percentage of perfused villi was calculated as
the number of perfused villi divided by the total number of villi
present in the high power field. Superscript
a P-value ,0.05
comparing the LPS-Cit with the LPS-Ala group. Superscript
b P-
value ,0.01 comparing LPS-Cit with the LPS-Arg group.
Superscript
c P-value ,0.05 comparing the control with the
LPS-Arg group. Superscript
d P-value ,0.01 comparing the NaCl-
Cit with the LPS-Arg group. Superscript
e P-value ,0.0001
comparing the control with the LPS-Ala group. Superscript
f P-
value ,0.01 comparing the control with the LPS-Arg group.
Superscript
g P-value ,0.0001 comparing the NaCl-Cit with the
LPS-Ala group. Superscript
h P-value ,0.01 comparing the NaCl-
Cit with the LPS-Ala group. Superscript
i P-value ,0.05
comparing LPS-Cit with the LPS-Arg group. Superscript
j P-
value ,0.01 comparing control with the LPS-Ala group. Data are
shown as mean 6 SEM. Statistical significance was determined
with one-way ANOVA with post-hoc Bonferroni correction
between groups.
(DOC)
Methods S1 Detailed information of material and methods used
in this study.
(DOC)
Video S1 Live imaging with SDF imager of the jejunal
microcirculation in the villi of control mouse. In this video
file the microcirculation is equally distributed in the villi, with a
continuous and homogeneous distribution of the perfusion in the
small and large vessels.
(AVI)
Video S2 Live imaging with SDF imager of the jejunal
microcirculation in the villi of LPS-Ala treated mouse.
The video shows a decreased perfusion of the microcirculation
with flow mainly persisting in the largest vessels.
(AVI)
Video S3 Live imaging with SDF imager of the jejunal
microcirculation in the villi of LPS-Arg treated mouse.
The video shows a comparable decreased perfusion of the
microcirculation as seen in the LPS-Ala treated mouse, with flow
mainly persisting in the largest vessels.
(AVI)
Video S4 Live imaging with SDF imager of the jejunal
microcirculation in the villi of LPS–Cit treated mouse. In
this video file, the smallest microcirculatory vessels are also
perfused. Furthermore, the perfusion is continuous and homoge-
neously distributed.
(AVI)
Video S5 Live imaging with SDF imager of the jejunal
microcirculation in the villi of NaCl-Cit treated mouse.
In this video the microcirculatory distribution is comparable to
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